PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Summary

This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.

Timeline

Start

2018-10-20

Primary completion

2020-03-30

Completion

2021-06-30

Drugs

Indications